title: [Efficacy of intranasal antihistamine in the treatment of allergic rhinitis: a meta-analysis].
abstract: OBJECTIVE
  To systematically evaluate the efficacy of intranasal antihistamine in the treatment of allergic rhinitis.
  
  
  METHODS
  The randomized controlled trials (RCT) about intranasal antihistamines for the treatment of allergic rhinitis between January 1985 and January 2014 were searched in OVID, PubMed, EMBASE, CNKI, WanFang Data and Cochrane Library. Two reviewers independently screened the literatures, extracted the data, and evaluated the methodological quality, then meta-analysis was performed by using RevMan 5.1 software.
  
  
  RESULTS
  A total of thirteen RCTs were included. The results of meta-analysis showed that the efficacy of intranasal antihistamine group was superior to the placebo group in total nasal symptom scores (TNSS), the difference was significant[WMD = -1.96, 95%CI (-2.06;-1.85), P < 0.01], and individual nasal symptom scores (blocked nose, rhinorrhea, and sneezing) [WMD = -0.18, 95%CI (-0.28;-0.08); WMD = -0.45, 95%CI (-0.52;-0.38); WMD = -0.41, 95%CI (-0.58;-0.24), all P < 0.01], with significant differences. There was no significant difference between the intranasal antihistamine group and the corticosteroid group in TNSS [WMD = -1.51, 95%CI (-3.51;0.49), P = 0.14], but the intranasal antihistamines group was superior to the corticosteroid group in individual nasal symptom scores (blocked nose, rhinorrhea, and sneezing) [WMD = -0.23, 95%CI (-0.40;-0.06); WMD = -0.35, 95%CI (-0.65;-0.05); WMD = -0.25, 95%CI (-0.42;-0.08), all P < 0.05], with significant differences. The intranasal antihistamine group was superior to the oral antihistamines group in TNSS [WMD = -0.88, 95%CI (-1.51;-0.25), P < 0.01].
  
  
  CONCLUSIONS
  Intranasal antihistamine is effective in the control of nasal symptoms in AR patients.
authors.affiliation: Department of Otolaryngology, Head and Neck Surgery, Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200092, China.
authors.forename: Shaoyan
authors.initials: S
authors.lastname: Feng
authors.forename: Chuntao
authors.initials: C
authors.lastname: Deng
authors.forename: Lei
authors.initials: L
authors.lastname: Li
authors.forename: Wei
authors.initials: W
authors.lastname: Liao
authors.forename: Yunping
authors.initials: Y
authors.lastname: Fan
authors.forename: Geng
authors.initials: G
authors.lastname: Xu
authors.affiliation: Email: noseli@163.com.
authors.forename: Huabin
authors.initials: H
authors.lastname: Li
mesh_terms: D000281:Administration, Intranasal; D000305:Adrenal Cortex Hormones; D018926:Anti-Allergic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006633:Histamine Antagonists; D006634:Histamine H1 Antagonists; D006801:Humans; D015508:Nasal Obstruction; D065631:Rhinitis, Allergic / Q000188:drug therapy*; D006255:Rhinitis, Allergic, Seasonal; D012984:Software
chemical_list: D000305:Adrenal Cortex Hormones; D018926:Anti-Allergic Agents; D006633:Histamine Antagonists; D006634:Histamine H1 Antagonists